Navigation Links
BUSM researcher awarded 2 NIH grants totaling over $11 million
Date:11/2/2011

(Boston) - Boston University School of Medicine (BUSM) researcher Robert Lafyatis, MD, recently was awarded two grants from the National Institutes of Health's (NIH) National Institute of Arthritis and Musculoskeletal and Skin Diseases. A 5-year, $8 million Centers of Research Translation (CORT) (P50) grant as well as a 5-year $3.3 million (P30) grant. Funding from both grants will be used to study systemic sclerosis (SSc) also known as scleroderma, a rare and complex rheumatic disease involving widespread scarring and vascular disease within multiple organ systems.

SSc remains one of the most difficult rheumatic diseases to manage, with limited effective therapies. These projects were designed to coordinate multiple scientists and clinicians to accelerate the understanding of the disease process through interactive patient-oriented studies into markers of disease activity, investigation of pathogenesis and trials of novel therapeutics.

The P50 grant will fund clinical research, identifying new paradigms for early phase clinical trials and molecular research into scleroderma pathogenesis. The P30 will allow the researchers at four sites: BUSM, University of Pittsburg Medical Center, Northwestern School of Medicine and Dartmouth Medical Center, to set up core services for scleroderma research, with the ultimate goal being a national resource for investigators studying scleroderma across the country.

One of the greatest impediments to finding new treatments is the heterogeneity of patient presentation and disease progression. Clinical markers are unable to predict onset and/or progression of the major complications, such as progressive fibrotic skin disease, pulmonary arterial hypertension and interstitial lung disease, each seen in a minority of SSc patients.

According to the researchers, identification of biomarkers permitting early recognition of these complications would potentially permit more targeted therapies, but also provide "at risk" populations for enrolling in therapeutic trials.

"Empowered by a very large SSc clinical population, we propose careful clinical evaluations, coupled with robust molecular approaches to identify skin, serum and peripheral blood mononuclear cell disease biomarkers," explained principal investigator Lafyatis, who also is a professor of medicine at BUSM.


'/>"/>

Contact: Gina DiGravio
gina.digravio@bmc.org
617-638-8480
Boston University Medical Center
Source:Eurekalert

Related medicine news :

1. Researchers map all the fragile sites of the yeast Saccharomyces cerevisiaes genome
2. UH Case Medical Center researchers publish promising findings for advanced cervical cancer
3. Researchers discover new way to kill pediatric brain tumors
4. Researchers Who Discovered First Genes for Stuttering will Present Findings to the National Stuttering Association
5. Tiny fruit fly could offer big clues in fight against obesity, researcher says
6. Researchers create drug to keep tumor growth switched off
7. MSU researcher linking breast cancer patients with alternative therapies
8. UT researcher receives $2.4 million to research obesity, high-risk pregnancy
9. Urine protein test might help diagnose kidney damage from lupus, UT Southwestern researchers find
10. GUMC researchers say flower power may reduce resistance to breast cancer drug tamoxifen
11. Clemson researchers develop hands-free texting application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... ... April 28, 2016 , ... ... solutions, announces today the availability of its latest software release, NetZoomDC 14.5. ... management and optimization, providing new analytical capabilities that assess complex capacity factors ...
(Date:4/28/2016)... ... 2016 , ... Amada Senior Care, premier provider of non-medical in-home care and ... San Antonio West location. Prior to entering the senior care industry, Amada franchise partner ... Amada San Antonio West will take place on Friday, April 29th. , ...
(Date:4/28/2016)... ... April 28, 2016 , ... Anzu®, ... announced a new Residency Education & Collaboration Platform for hospitals and medical ... and a host of collaboration tools designed to improve patient outcomes through ...
(Date:4/28/2016)... ... April 28, 2016 , ... April, 28, ... Top Doc in Physical Medicine and Rehabilitation by Philadelphia Magazine. , Philadelphia Magazine’s ... by randomly surveying physicians and medical leadership across the country. These select individuals ...
(Date:4/28/2016)... ... 2016 , ... SyncDog, Inc. , the leading ISV ... workstation suite, SentinelSecure™, at MobileIron’s 6th annual Mobile First Conference in San Francisco, ... 6th Mobile First Conference and will feature immersive training, collaboration, and connections with ...
Breaking Medicine News(10 mins):
(Date:4/26/2016)... -- US demand for infection prevention products and ... to $27.6 billion in 2020.  Increasing pressures on ... of healthcare-associated infections (HAIs) will boost revenues generated ... declining, the overall rate of certain HAIs in ... the CDC.  Recent statistics indicate that only 25 ...
(Date:4/26/2016)... April 26, 2016 Bayer AG ... interest, taxes, depreciation and amortization. The earnings are the ... multinational,s best-selling drugs Xarelto and Eylea, drugs Bayer is ... Xarelto,s patent expiration date was extended by four years ... market is expected to reach a value of ...
(Date:4/26/2016)... YORK , April 26, 2016 /PRNewswire/ ... report "Global Microbial identification Market Size, Share, ... - Industry Insights by Product (Consumables, Instruments ... Method and Genotypic Method), by Application (Diagnostic ... and Environmental Application) and by End User ...
Breaking Medicine Technology: